SCHEMBL18735361

SCHEMBL18735361

CCOC(=O)CC(=O)C(=O)SCC(NC(=O)C(C)CC)C(=O)OCC

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ KMT2A Q03164 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ MGAM O43451 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ SI P14410 1/20 0.36
▸ MGAM2 Q2M2H8 1/20 0.36
▸ METAP2 P50579 8/20 0.35
▸ METAP1 P53582 6/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ PPID Q08752 1/20 0.32
▸ CAD P27708 1/20 0.32
▸ ACE P12821 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18735330 0.94 CYP2C9 (0.36) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18735365 0.91 CYP1A2 (0.35) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18734956 0.87 MGAM (0.32) MGAMGAASIMGAM2METAP2
SCHEMBL18735070 0.86 CYP1A2 (0.41) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18735349 0.83 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18735335 0.82 L3MBTL1 (0.47) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18735337 0.81 CYP1A2 (0.36) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18735054 0.80 CYP2C9 (0.38) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18735314 0.79 METAP2 (0.35) CYP1A2CYP2C9CYP2C19HTTL3MBTL1
SCHEMBL18735067 0.78 CYP1A2 (0.36) CYP1A2CYP2C9CYP2C19HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017060400-A1 PROTECTED CARBOXYLIC ACID-BASED METABOLITES FOR THE TREATMENT OF DISESASES RELATED TO MITOCHONDRIAL DYSFUNCTIONS NEUROVIVE PHARMACEUTICAL AB (SE) 2017-04-13 — — WO disclosed
Send feedback